Plain-English translation of NCT06585345 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 1/2 — A combined trial that checks safety and dosing while also starting to look at whether the treatment works.
This trial is testing whether CD7 CAR-T cells—a type of immune cell therapy designed to fight leukemia—can help patients whose blood cancer has stopped responding to standard chemotherapy or has returned. Researchers will carefully increase the dose of these cells to find the safest and most effective amount, then track how well the treatment works and any side effects over two years.
Standard chemotherapy doesn't work well for many patients with relapsed or refractory acute leukemia, leaving them with few good treatment options. This medication takes advantage of the body's own immune system to target cancer cells in a new way, offering hope to patients who have run out of conventional choices.
You likely qualify if…
You likely don't qualify if…
If you join this study, you will receive CD7 CAR-T cells through infusion, starting with a low dose and gradually increasing to find the safest effective level—similar to how many cancer treatments are given. You'll have regular clinic visits to check your blood work, imaging scans, and overall health. The study will monitor you closely for side effects (including infections, bleeding, and neurological symptoms) and measure how well the treatment is working for up to 24 months after your infusion.
AI-generated summary from trial data · Jun 3, 2026 · Not medical advice
China